Table 2.

Patient and tumor characteristics by PIK3CA mutation type

CharacteristicWT (N = 398)Mutation type
HS (n = 142)HS kinase (n = 88)HS helical (n = 54)
n (%)n (%)P*n (%)P*n (%)P*
Age (y)
    Median (range)57 (27-89)61 (33-89)0.00457 (27-89)0.163 (35-88)0.004
    <50123 (31%)28 (20%)0.0321 (24%)0.427 (13%)0.02
    50-69195 (49%)78 (55%)47 (53%)31 (57%)
    ≥7080 (20%)36 (25%)20 (23%)16 (30%)
Menopausal status
    Pre118 (30%)29 (20%)0.0320 (23%)0.179 (17%)0.04
    Post274 (69%)113 (80%)68 (77%)45 (83%)
    N/A6 (2%)
Race
    Caucasian315 (79%)113 (80%)0.2468 (77%)0.4845 (83%)0.26
    Black37 (9%)12 (8%)10 (11%)2 (4%)
    Asian9 (2%)7 (5%)4 (5%)3 (6%)
    Hispanic17 (4%)2 (1%)1 (1%)1 (2%)
    Other12 (3%)6 (4%)3 (3%)3 (6%)
    Unknown8 (2%)2 (1%)2 (2%)
Tumor size (mm)
    Median (range)20 (1-150)18 (0-80)0.0118 (0-70)0.0219.5 (1-80)0.16
T stage
    T01 (0%)0.060.100.52
    T1207 (52%)92 (65%)58 (66%)34 (63%)
    T2166 (42%)45 (32%)27 (31%)18 (33%)
    T316 (4%)4 (3%)3 (3%)1 (2%)
    T48 (2%)1 (1%)1 (2%)
Nodal status
    Negative190 (48%)82 (58%)0.0356 (64%)0.00726 (48%)0.87
    Positive177 (44%)49 (35%)26 (30%)23 (43%)
    Unknown31 (8%)11 (8%)6 (7%)5 (9%)
N stage
    N0190 (48%)82 (58%)0.1756 (64%)0.0526 (48%)0.95
    N192 (23%)24 (17%)13 (15%)11 (20%)
    N237 (9%)13 (9%)7 (8%)6 (11%)
    N347 (12%)12 (8%)6 (7%)6 (11%)
    Unknown32 (8%)11 (8%)6 (7%)5 (9%)
Stage
    I128 (32%)63 (44%)0.0644 (50%)0.0219 (35%)0.78
    II144 (36%)40 (28%)22 (25%)18 (33%)
    III83 (21%)26 (18%)14 (16%)12 (22%)
    IV18 (5%)4 (3%)3 (3%)1 (2%)
    Unknown24 (6%)9 (6%)5 (6%)4 (7%)
Grade
    111 (3%)12 (8%)<0.00016 (7%)0.00046 (11%)<0.0001
    2116 (29%)69 (49%)41 (47%)28 (52%)
    3225 (57%)45 (32%)32 (36%)13 (24%)
    N/A/Unknown46 (12%)16 (11%)9 (10%)7 (13%)
Histology
    Ductal318 (80%)117 (82%)0.1772 (82%)0.1645 (83%)0.73
    Lobular38 (10%)14 (10%)8 (9%)6 (11%)
    Ductal, lobular18 (5%)9 (6%)7 (8%)2 (4%)
    Special type23 (6%)2 (1%)1 (1%)1 (2%)
Lymphovascular invasion
    Negative205 (52%)76 (54%)0.7948 (55%)0.6428 (52%)0.89
    Positive140 (35%)49 (35%)29 (33%)20 (37%)
    Unknown53 (13%)17 (12%)11 (13%)6 (11%)
ER
    Negative142 (36%)30 (21%)0.000319 (22%)0.00411 (20%)0.01
    Positive225 (57%)108 (76%)67 (76%)41 (76%)
    Unknown31 (8%)4 (3%)2 (2%)2 (4%)
PR
    Negative173 (43%)40 (28%)0.000322 (25%)0.000318 (33%)0.12
    Positive189 (47%)94 (66%)62 (70%)32 (59%)
    Unknown36 (9%)8 (6%)4 (5%)4 (7%)
HR
    Negative116 (29%)17 (12%)<0.000110 (11%)0.00027 (13%)0.007
    Positive251 (63%)120 (85%)75 (85%)45 (83%)
    Unknown31 (8%)5 (4%)3 (3%)2 (4%)
HER2
    Negative281 (71%)120 (85%)0.000573 (83%)0.0147 (87%)0.01
    Positive54 (14%)5 (4%)4 (5%)1 (2%)
    Unknown63 (16%)17 (12%)11 (13%)6 (11%)

NOTE: Statistical tests are based on available data; duct carcinoma in situ, unknown, and N/A not included in P value calculation.

  • 2 test used for binary/categorical variables; t test used for continuous variables.

  • Pathology review identified one ductal carcinoma in situ (T0) without invasive cancer.

  • Lobular carcinomas and tumors with special type histology were not analyzed for grade and are designated N/A.